Conflict of interest: Dr Tsai has conducted clinical trials, received honoraria for serving as a consultant or received speaking fees from Wyeth Pharmaceuticals (now Pfizer), Serono International SA (now Merck Serono International), UniPharma/Biogen Idec, Janssen-Cilag Pharmaceuticals and Abbott Pharmaceuticals. Drs Cho, Chen and Chiu have no conflicts of interest to declare.
1346-8138/asset/JDE_left.gif?v=1&s=3781b10872dbdb403261db72c2585d845f259fc1)
1346-8138/asset/JDE_right.gif?v=1&s=a7c25c56af4096e2045f196a64e230d6768f60d0)
ORIGINAL ARTICLE
You have free access to this content
Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan
Article first published online: 14 NOV 2011
DOI: 10.1111/j.1346-8138.2011.01434.x
© 2011 Japanese Dermatological Association
Issue
The Journal of Dermatology
Special Issue: Special Issue: Psoriasis (pages 211-289)
Volume 39, Issue 3, pages 269–273, March 2012
Additional Information
How to Cite
CHO, Y.-T., CHEN, C.-H., CHIU, H.-Y. and TSAI, T.-F. (2012), Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan. The Journal of Dermatology, 39: 269–273. doi: 10.1111/j.1346-8138.2011.01434.x
Publication History
- Issue published online: 21 FEB 2012
- Article first published online: 14 NOV 2011
- Received 2 August 2011; accepted 27 September 2011.
References
- 1, , et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–2022.
- 2, , , . Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol 2003; 30: 1624–1625.
- 3, , et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788–789.
- 4, , et al. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol 2008; 43: 397–401.
- 5, , et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718–720.
- 6, , . Safety of anti-tumor necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011; 25: 471–474.
- 7, , et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36: 1188–1194.
- 8, , et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352–1355.
- 9, , , , , . Safety of antitumor necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 2010; 162: 1408–1410.
- 10, , , . Chronic viral hepatitis and TNF-alpha blockade. Rheumatology (Oxford) 2007; 46: 1381; author reply -2.
- 11, , et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62: 749–754.
- 12, . Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–662.
- 13, . Global epidemiology of Hepatitis B virus (HBV) infection. NAJMS 2011; 4: 7–13.
- 14
- 15, , et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519–528.
- 16, , . Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983–989.
- 17, , . The impact of treatment with tumor necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217–1228.
- 18, . Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010; 29: 1021–1029.
- 19, , et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40–46.
- 20, , et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987–1019.
- 21, , et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1–70.Direct Link:
- 22, . The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 2008; 59: 757–759.
- 23, , et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826–850.
- 24, . Lok. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 275–284.
- 25, , et al. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007; 46: 1057–1070.
- 26
- 27, . Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38: 208–217.